Invasive cancers are not necessarily from preformed in situ tumours - an alternative way of carcinogenesis from misplaced stem cells

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 7, 2013, Pages 921-926

  Wang, Rui An ^a,b   Li, Zeng Shan ^a,b   Zhang, Hui Zhong ^c   Zheng, Ping Ju ^d   Li, Qin Long ^a,b   Shi, Jian Guo ^a,b   Yan, Qing Guo ^a,b   Ye, Jing ^a,b   Wang, Jing Bo ^a,b   Guo, Ying ^a,b   Huang, Xiao Feng ^a   Yu, Ying Hao ^e  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d Chang'an Hospital   (China)

^e FUZHOU GENERAL HOSPITAL   (China)

Author keywords

Basement membrane; Breast cancer; Carcinogenesis; DCIS; quasi cancer; Stem cell misplacement theory; Stroma

Indexed keywords

TELOMERASE;

ANIMAL; BASEMENT MEMBRANE; BREAST CANCER; BREAST TUMOR; CARCINOGENESIS; CONNECTIVE TISSUE; CYTOLOGY; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATION; INTRADUCTAL CARCINOMA; METABOLISM; METASTASIS; MOUSE; MUTATION; NEOPLASM; NOTE; PAGET NIPPLE DISEASE; PATHOLOGY; QUASI-CANCER; STEM CELL; STEM CELL MISPLACEMENT THEORY; STROMA; TUMOR INVASION;

BASEMENT MEMBRANE; BREAST CANCER; CARCINOGENESIS; DCIS; QUASI-CANCER; STEM CELL MISPLACEMENT THEORY; STROMA;

ANIMALS; BASEMENT MEMBRANE; BREAST NEOPLASMS; CARCINOGENESIS; CARCINOMA, DUCTAL, BREAST; CONNECTIVE TISSUE; DISEASE PROGRESSION; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; MICE; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; STEM CELLS; TELOMERASE;

EID: 84880828444     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12078     Document Type: Note

References (26)

1. Gusterson BA, Machin LG, Gullick WJ, et al. Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer. Int J Cancer. 1988; 42: 842-5.
2. van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988; 319: 1239-45.
3. Schimmelpenning H, Eriksson ET, Falkmer UG, et al. Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma. Virchows Arch A Pathol Anat Histopathol. 1992; 420: 433-40.
4. Bartkova J, Barnes DM, Millis RR, et al. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol. 1990; 21: 1164-7.
5. Barnes DM, Bartkova J, Camplejohn RS, et al. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer. 1992; 28: 644-8.
6. Latta EK, Tjan S, Parkes RK, et al. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol. 2002; 15: 1318-25.
7. Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992; 10: 599-605.
8. Guerin M, Barrois M, Terrier MJ, et al. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res. 1988; 3: 21-31.
9. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-82.
10. Virnig BA, Tuttle TM, Shamliyan T, et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010; 102: 170-8.
11. Sanders ME, Schuyler PA, Dupont WD, et al. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005; 103: 2481-4.
12. Jo BH, Chun YK. Heterogeneity of invasive ductal carcinoma: proposal for a hypothetical classification. J Korean Med Sci. 2006; 21: 460-8.
13. Frykberg ER. Lobular carcinoma in situ of the breast. Breast J. 1999; 5: 296-303.
14. Alberts B, Johnson A, Lewis J, et al. Molecular biology of the cell, 4th edn. New York: Garland Science, 2002.
15. Stern R. Association between cancer and "acid mucopolysaccharides": an old concept comes of age, finally. Semin Cancer Biol. 2008; 18: 238-43.
16. Martins VL, Vyas JJ, Chen M, et al. Increased invasive behaviour in cutaneous squamous cell carcinoma with loss of basement-membrane type VII collagen. J Cell Sci. 2009; 122: 1788-99.
17. Wang RA, Li QL, Li ZS, et al. Apoptosis drives cancer cells proliferate and metastasize. J Cell Mol Med. 2013; 17: 205-11.
18. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318: 1108-13.
19. Ledford H. Cancer theory faces doubts. Nature. 2011; 472: 273.
20. Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res. 2005; 65: 5996-6000; discussion-1.
21. Zhang LJ, Li H, Zhang LY, et al. Metastasis: inherent versus acquired phenotype. Med Hypotheses. 2010; 74: 874-6.
22. Lipponen P, Aaltomaa S, Tammi R, et al. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur J Cancer. 2001; 37: 849-56.
23. Setala LP, Tammi MI, Tammi RH, et al. Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate. Br J Cancer. 1999; 79: 1133-8.
24. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 57-70.
25. Hiyama E, Hiyama K. Telomere and telomerase in stem cells. Br J Cancer. 2007; 96: 1020-4.
26. Soto AM, Sonnenschein C. The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. BioEssays. 2011; 33: 332-40.